Active Public Health & Healthcare Infection & Immunity

Hilleman Business Plan FY2025-FY2030

Funder Wellcome Charity-funded
Recipient organisation Hilleman Laboratories Singapore Pte LTD
Other organisations recorded by Europe PMC MSD Wellcome Trust Hilleman Laboratories Pvt. LTD These are researcher affiliations; the award is counted once under the primary recipient above.
Funding £28.0M
Period Mar 2025 — Mar 2029

In plain English

AI plain-English summary

Hilleman is scaling up its vaccine manufacturing and development operations across multiple platforms, from cholera and meningitis to mRNA and recombinant vaccines. This matters because many infectious diseases that disproportionately affect low- and middle-income countries lack affordable, accessible vaccines. Hilleman is working to close that gap by advancing a pipeline that includes vaccines for Nipah, Lassa fever, Q-Fever, and meningitis, as well as a second-generation Ebola vaccine. The organisation is also building manufacturing capacity through its ACES facility, which will produce GMP batches for clinical trials and eventual distribution. If successful, these vaccines could reduce disease burden for populations in LMICs, including through the rollout of Hillchol™ in India and GAVI-eligible countries. The work also supports pandemic preparedness by developing vaccines against "Disease X" threats. Beyond direct health impact, the project strengthens global vaccine infrastructure by investing in platform technologies and securing long-term operational funding from partners such as the Singapore Economic Development Board. This is applied research with a clear public health mission: to turn vaccine candidates into licensed products that reach the people who need them most.

View original technical description
Since April 2021, Hilleman expanded its vaccine portfolio from cholera and meningitis to viral, recombinant and mRNA vaccines. We invested in four vaccine platforms and raised $39.1M in external funding to support our infrastructure and operations. From 2025-2027, we will oversee the implementation of Hillchol™in India and GAVI countries, complete the development and licensure of Ervebo® second generation with our collaborators, advance MenACWYX, CircRNA-Nipah, Lassa and Q-Fever vaccines to Phase I through external funding and partnerships, and manufacture 5 GMP batches at ACES. We will secure $10M from Singapore EDB to support ACES operations, $21M for Disease X vaccines and secure funding through grants (UKRI, CEPI, BMGF) and out licensing revenues from commercial partnerships. From April 2027, we expect to receive $3M/year from EDB to support ACES operations and extend EDB grant support for 43 FTEs beyond 2026, develop Hillchol-rCTB, oversee the licensure of Lassa, MenACWYX, advance vaccines against sevaral endemic diseases to Phase II, and manufacture forty 44 GMP batches. The implementation of Hillchol™, Ervebo®, Lassa, Nipah and MenACWYX vaccines could impact disease burden for 150M people in LMICs with a potential for 500M more with vaccines against other endemic diseases.

View the original record at the funder ↗

Researchers

ALAIN Bouckenooghe (EPMC Awardee)Erlyani Hamid (EPMC Awardee)Serene Tan (EPMC Awardee)lawrence yap (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Room temperature stable MVA-GP pox vectored vaccine against CCHF
Development of a subunit vaccine against CCHF virus for use in low-middle income countries; completion of pre-clinical studies
CCHFv vaccine for LMICs - transition from preclinical to clinical studies
Crimean-Congo Haemorrhagic Fever Vaccine
Advancing Vaccine Development: Harnessing Multiple Antigenic Epitopes for Crimean-Congo Hemorrhagic Fever in Humans and Animals

Original classification

Discretionary Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.